Welcome to the 10th edition of our event New updates in Drug Formulation & Bioavailability.
This event is based on the concept of synergies between “science” and “business”. Meet R&D people, the pharma industry, increase your awareness and gain more knowledge about this exciting topic.
The presented content and topics will focus on advancements in formulations and cutting edge technologies that can allow cheaper, safer and effective drugs. Pharmaceutical formulation can have a huge impact on the bioavailability of a given drug and is one of the key factors in the successful development of drug delivery systems.
However, many of the APIs in the development pipelines often possess poor physico-chemical properties, which make them difficult to formulate using classic approaches and hence require the use of new and enabling formulation approaches.
Date: September 6th 2022
Time: 9:00 – 16:00
Venue: Medicon Valley Alliance, Edvard Thomsens Vej 14, 2300 København – Auditorium
The meeting will include pre-bookable face-to-face-meetings and will be covered by the media.
Topics will include:
- Formulation development design space
- Improving bioavailability of poorly soluble compounds
- Controlled and modified release technologies
- Out-sourcing and in-licensing
- Exploring different routes of administration in enhancing macromolecule delivery
The target audience consists of:
- Drug formulation professionals from Big Pharma, CDMO’s, Academia
- Early Phase & virtual biotech and pharma companies
- QA & Reg Aff. Managers
- Procurement Managers
- Speakers will come from: Pharmaceutical companies, Excipient manufacturers, CDMO’s, Academia
Program
| 8:30 | Registration, 1-2-1 partnering meetings and networking at the exhibiton |
| 09:00 | Welcome and introduction Korbinian Löbmann, University of Copenhagen |
| 09:05 | The Viscosity Reduction Platform – Enabling subcutabeous delivery Tobias Rosenkranz, Merck |
| 09:35 | Protein self-assembled materials for drug delivery Vito Foderá, University of Copenhagen |
| 10:05 | Formulation of lipid nanoparticles for drug delivery Anna Fureby, Director NextBioForm and Senior scientist RI:SE |
| 10:35 | Coffee, 1-2-1 partnering meetings and networking at the exhibiton |
| 11:20 | AmorphOXTM – a novel drug delivery platform Robert Rönn, Orexo |
| 11:50 | Improved biopharmaceutical properties for novel oral dosage forms og protein kinase Inhibitiors – a potential new standard of care for chronic myeloid lymphoma Charlotta Liljebris, Xspray Pharma |
| 12:20 | Lunch, 1-2-1 partnering meetings and networking at the exhibiton |
| 11:30 | How to accelerate Scandinavian life science company funding Johan Kördel, Ph.D. Assoc Prof. Founding |
| 11:50 | Research and Drug development – not the same game Maria Lundberg, CEO SDS Life Science |
| 12:10 | Focus on accelerating the growth of the biotech to ensure sustainable future across life science Bassem Saleh, CEO TFS HealthScience |
| 12:30 | Find scientific expertise anywhere in the world Francesco Ruospo, CBO AcademicLabs |
| 12:35 | Lunch, 1-2-1 partnering meetings and networking at the exhibiton |
| 13:40 | What can we learn from drug properties to make sensible decisions about the development of amorphous solid dosage forms? Thomas Rades, University of Copenhagen |
| 14:10 | Solving the Insoluble – A eutectic approach to enhancing bioavailability Niall Hodgins, Seranovo |
| 14:40 | New updates in formulation development Anna Runsjö, Zelmic |
| 15:10 | Coffee, 1-2-1 partnering meetings and networking at the exhibiton |
| 15:40 | TBA Speaker TBA, catalent |
| 16:10 | ICOone Nasal – Novel system for combined nasal and pulmonary drug delivery Orest Lastow, Iconovo |
| 16:40 | Conclusion Korbinian Löbmann, University of Copenhagen |
Speakers
To know more about the speakers viste:
Speakers & Papers – New updates in Drug Formulation & Bioavailability 2022 (formulationsbioavailability.com)
| Organized by | In collaboration with |
|
 |